PReS-FINAL-2107: In vitro investigation into mesenchymal stromal cells as a potential therapeutic in juvenile arthritis

por Wienke, J, De Roock, S, Swart, J, Martens, A, Wulffraat, N, Prakken, B
Publicado 2013

Mesenchymal stromal cells suppress synovial fluid-derived t cells from juvenile idiopathic arthritis patients in vitro

por Wienke, J, de Roock, S, Swart, J, Martens, A, Wulffraat, N, Prakken, B
Publicado 2014

PReS-FINAL-2100: Methotrexate treatment affects effector, but not regulatory T cells in juvenile idiopathic arthritis

por Vastert, S, Bulatovic-Calasan, M, Scholman, R, Klein, M, Wulffraat, N, Prakken, B, Wijk, FV
Publicado 2013

The TLR4 ligands MRP8 and MRP14 in the diagnosis and pathogenesis of systemic onset juvenile idiopathic arthritis

por Frosch, M, Viemann, D, Wittkowski, H, Foell, D, Vogl, T, Barczyk, K, Wulffraat, N, Roth, J
Publicado 2008

PReS-FINAL-2116: Assessment of disease activity by patients with juvenile idiopathic arthritis and the parents compared to the assessment by pediatric rheumatologists

por Armbrust, W, Kaak, J, Bouma, J, Lelieveld, O, Wulffraat, N, Sauer, P, van Sonderen, E
Publicado 2013

PReS-FINAL-2342: Anti-TNFALPHA therapy targeys PKB/C-AKT induced resistance of effector cells to suppression in juvenile arthritis

por Wehrens, E, Vastert, S, Mijnheer, G, Meerding, J, Klein, M, Wulffraat, N, Prakken, B, van Wijk, F
Publicado 2013

Evidence-based diagnosis and treatment of macrophage activation syndrome in systemic juvenile idiopathic arthritis

por Boom, V., Anton, J., Lahdenne, P., Quartier, P., Ravelli, A., Wulffraat, N.M., Vastert, S.J.
Publicado 2015

PReS-FINAL-2162: Development of a risk model to predict methotrexate intolerance in juvenile idiopathic arthritis

por Van Dijkhuizen, P, Bulatovic-Calasan, M, Pluijm, S, De Rotte, M, Vastert, B, Kamphuis, S, De Jonge, R, Wulffraat, N
Publicado 2013

PReS-FINAL-1015: A systematic literature review on diagnosis and treatment of pediatric rheumatic diseases: a shared initiative

por Boom, V, de Graeff, N, Belutti Enders, F, Groot, N, ter Haar, N, Sperotto, F, Vastert, S, Wulffraat, N
Publicado 2013

Autologous stem cell transplantation in autoimmune arthritis restores immune homeostasis by renewal of the natural Treg compartment

por van den Broek, T, Delemarre, E, Meerding, J, Wehrens, E, Broere, F, Wulffraat, N, Boes, M, Prakken, B, van Wijk, F
Publicado 2011

PReS-FINAL-1006: Autologous bone marrow transplantation in autoimmune, experimental arthritis restores immune homeostasis by renewal of the natural tregs compartment

por van den Broek, T, Delemarre, E, Meerding, J, Wehrens, E, Broere, F, Wulffraat, N, Boes, M, Prakken, B, van Wijk, F
Publicado 2013

Use of the JADAS criteria to assess efficacy of canakinumab in patients with SJIA – an analysis of 12-week pooled data

por Ravelli, A, Brunner, HI, Ruperto, N, Quartier, P, Consolaro, A, Wulffraat, N, Lheritier, K, Gaillez, C, Martini, A, Lovell, DJ
Publicado 2014

Maintenance of efficacy of canakinumab in SJIA at the individual patient level in a 12-week pooled dataset

por Ravelli, A, Brunner, HI, Ruperto, N, Quartier, P, Consolaro, A, Wulffraat, N, Lheritier, K, Gaillez, C, Martini, A, Lovell, DJ
Publicado 2014

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic J...

por Ruperto, N, Quartier, P, Wulffraat, N, Woo, P, Loy, A, Mouy, R, Bader-Meunier, B, Prakken, B, Noseda, E, Rordorf, C
Publicado 2008

PReS-FINAL-2139: Tapering and withdrawal of tocilizumab in patients with systemic JIA in inactive disease: results from an alternative dosing regimen in the tender study

por De Benedetti, F, Ruperto, N, Brunner, HI, Grom, A, Wulffraat, N, Henrickson, M, Jerath, R, Kimura, Y, Kadva, AK, Wang, J, Martini, A, Lovell, D
Publicado 2013

Tapering and withdrawal of tocilizumab in patients with systemic juvenile idiopathic arthritis in inactive disease: results from an alternative dosing regimen in the TENDER study

por De Benedetti, F, Ruperto, N, Brunner, H, Grom, A, Wulffraat, N, Henrickson, M, Jerath, R, Kimura, Y, Kadva, AK, Wang, J, Martini, A, Lovell, D
Publicado 2014

When and how to stop etanercept after successful treatment of patients with juvenile idiopathic arthritis

por Prince, FHM, Twilt, M, Simon, SCM, van Rossum, MAJ, Armbrust, W, Hoppenreijs, EPAH, Kamphuis, SSM, van Santen-Hoeufft, M, Koopman-Keemink, Y, Wulffraat, N, ten Cate, R, van Suijlekom-Smit, LWA
Publicado 2008

PReS-FINAL-2158: Effect of canakinumab on functional ability and health-related quality of life in systemic juvenile idiopathic arthritis (SJIA) patients

por Quartier, P, Ruperto, N, Wulffraat, N, Brunner, H, Brik, R, Mccann, L, Foster, H, Frosch, M, Gerloni, V, Harel, L, Len, C, Houghton, K, Joos, R, Abrams, K, Lheritier, K, Kessabi, S, Martini, A, Lovell, D
Publicado 2013

Resetting the Adaptive Immune System After Autologous Stem Cell Transplantation: Lessons from Responses to Vaccines

por Brinkman, D. M. C., Jol-van der Zijde, C. M., ten Dam, M. M., te Boekhorst, P. A. W., ten Cate, R., Wulffraat, N. M., Hintzen, R. Q., Vossen, J. M., van Tol, M. J. D.
Publicado 2007

Outcomes of hematopoietic stem cell transplantation for Hurler's syndrome in Europe: a risk factor analysis for graft failure

por Boelens, J J, Wynn, R F, O'Meara, A, Veys, P, Bertrand, Y, Souillet, G, Wraith, J E, Fischer, A, Cavazzana-Calvo, M, Sykora, K W, Sedlacek, P, Rovelli, A, Uiterwaal, C S P M, Wulffraat, N
Publicado 2007